Elizabeth S. Hickford

Elizabeth S. Hickford

Auto-generated profile, based on publicly available information

Elizabeth S. Hickford

Precision Medicine, UCB Biopharma, 208 Bath Road, Slough, SL1 3WE, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DLDaniel J. Lightwood
Daniel J. Lightwood
RMRebecca J. Munro
Rebecca J. Munro
JPJohn Porter
John Porter
DMDavid McMillan
David McMillan
BCBruce Carrington
Bruce Carrington
ALAlastair D. G. Lawson
Alastair D. G. Lawson
We have recently described the development of a series of small-molecule inhibitors of human tumour necrosis factor (TNF) that stabilise an open, asymmetric, signalling-deficient form of the soluble TNF trimer. Here, we describe the generation, characterisation, and utility of a monoclonal antibody that selectively binds with high affinity to the asymmetric TNF trimer–small molecule complex. The antibody helps to define the molecular dynamics of the apo TNF trimer, reveals the mode of action and specificity of the small molecule inhibitors, acts as a chaperone in solving the human TNF–TNFR1 complex crystal structure, and facilitates the measurement of small molecule target occupancy in complex biological samples. We believe this work defines a role for monoclonal antibodies as tools to facilitate the discovery and development of small-molecule inhibitors of protein–protein interactions.

1 July 2023 in Bioanalysis
Verified
Journal Article
Open access
EHElizabeth S Hickford
Elizabeth S Hickford
LDLien Dejager
Lien Dejager
DYDaisy Yuill
Daisy Yuill
AKApoorva Kotian
Apoorva Kotian
SSSucharita Shankar
Sucharita Shankar
PCPaul Cutler
Paul Cutler
It is widely acknowledged by the bioanalytical and biomarker community that biomarker assay validations should be fit-for-purpose depending on the context of use. The challenge is how to consistent...

15 October 2024 in Bioanalysis
Verified
Journal Article
Open access
ASAchani M Silva
Achani M Silva
EHElizabeth S Hickford
Elizabeth S Hickford
PCPaul Cutler
Paul Cutler
The link between alpha Synuclein (α-Syn) phosphorylation and Parkinson's disease pathogenesis has not been fully elucidated, in part due to analytical methods with finite specificity and sensitivity, resulting in conflicting data on pathophysiological levels of the protein.One factor hindering the assessment of the role of pSer129 α-Syn is the lack of a fit for purpose assay. Antibodies were assessed for quantification of pSer129 α-Syn, resulting in a sensitive and specific assay suitable for use in Parkinson's disease and control CSF, with no significant difference found between the two populations. Total α-Syn was measured using a commercial kit, demonstrating a positive correlation between total and pSer129 α-Syn.This adds to available methods for pSer129 α-Syn in support of α-synucleinopathy research.

17 April 2024 in Bioanalysis
Verified
Journal Article
Open access
LDLien Dejager
Lien Dejager
SBSophia Banton
Sophia Banton
PMPatricia Marques
Patricia Marques
GRGabriela Rinikova
Gabriela Rinikova
SLSabrina Lory
Sabrina Lory
SGSasker Grootjans
Sasker Grootjans
Ligand-binding assays (LBAs) rely on the reversible, noncovalent binding between the analyte of interest and the assay reagents, and understanding their dynamic equilibrium is key to building robust LBA methods. Although the dynamic interplay of free and bound fractions can be calculated using mathematical models, these are not routinely applied. This approach is costly in terms of both assay development time and reagents, and can result in an under-exploration of the possible parameter combinations. Therefore, we have created a user-friendly simulation tool to facilitate LBA development (the BiSim Tool). We describe the models driving the mathematical simulations and the main features of our software solution by means of case studies, illustrating the tool's value in drug development. To support drug development for all patients worldwide, the BiSim Tool is now available as an open-source code project and as a free web-based tool at https://proteinbindingsimulation.shinyapps.io/BiSim-ProteinBindingSimulation [].

1 March 2023 in Bioanalysis
Verified
Journal Article
Closed access
EHElizabeth S Hickford
Elizabeth S Hickford
JOJames O'COnnell
James O'COnnell
AMAlison Maloney
Alison Maloney
PFPeter Florian
Peter Florian
GJGeoffrey I Johnston
Geoffrey I Johnston
TBTim Bourne
Tim Bourne
Background: An antibody specific to small-molecule inhibitor-bound TNF has enabled the development of target occupancy biomarker assays to support the development of novel treatments for autoimmune...